ArticlePharmaceutical research1998
Liposomes dispersed within a thermosensitive gel: a new dosage form for ocular delivery of oligonucleotides.
Article in Pharmaceutical research, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 118 citations in OpenAlex.
- Non-Viral Delivery Systems to Transport Nucleic Acids for Inherited Retinal Disorders.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Development and Characterization of Thermosensitive and Bioadhesive Ophthalmic Formulations Containing Flurbiprofen Solid Dispersions.Gels (Basel, Switzerland) · 2024Article
- Mucoadhesive Poloxamer-Based Hydrogels for the Release of HP-β-CD-Complexed Dexamethasone in the Treatment of Buccal Diseases.Pharmaceutics · 2021Article
- Emerging Nano-Formulations and Nanomedicines Applications for Ocular Drug Delivery.Nanomaterials (Basel, Switzerland) · 2021Review
- Pharmacotechnical Development of a Nasal Drug Delivery Composite Nanosystem Intended for Alzheimer's Disease Treatment.Pharmaceutics · 2020Article
- Drug-Loaded Biocompatible Nanocarriers Embedded in Poloxamer 407 Hydrogels as Therapeutic Formulations.Medicines (Basel, Switzerland) · 2018Review
- Advanced drug delivery and targeting technologies for the ocular diseases.BioImpacts : BI · 2016Review
- Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation.Nanoscale · 2013Review
- Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems.Pharmaceutics · 2012Article
- Thermoreversible Pluronic F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies.International journal of nanomedicine · 2011Article
- Preparation and pharmaceutical/pharmacodynamic evaluation of topical brucine-loaded liposomal hydrogel.Journal of materials science. Materials in medicine · 2009Article
- Calcein release from polymeric vesicles in blood plasma and PVA hydrogel.Pharmaceutical research · 2009Article
- Preparation and evaluation of thermosensitive liposomal hydrogel for enhanced transcorneal permeation of ofloxacin.AAPS PharmSciTech · 2009Article
- A review of poloxamer 407 pharmaceutical and pharmacological characteristics.Pharmaceutical research · 2006Review
- Oligonucleotide-polyethylenimine complexes targeting retinal cells: structural analysis and application to anti-TGFbeta-2 therapy.Pharmaceutical research · 2006Article
- Hydrophilic absorbable copolyester exhibiting zero-order drug release.Pharmaceutical research · 2006Article
- Cyclodextrin-mediated drug release from liposomes dispersed within a bioadhesive gel.Pharmaceutical research · 2005Article
- The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides.Biomaterials · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe main goal of this study was to develop an ocular controlled release formulation of a model oligonucleotide (pdT16), contained within liposomes dispersed within a thermosensitive gel composed by poloxamer 407.
methodsThe influence of the poloxamer concentration 2% or 27% on the stability of the liposomes (PC: CHOL and PC: CHOL: PEG-DSPE) was investigated. The in vitro release profiles of pdT16 from various poloxamer formulations (free pdT16 dispersed within 20% and 27% poloxamer gels, pdT16 encapsulated within liposomes dispersed within 20% and 27% poloxamer gels) were realized using a membrane-free release model.
resultsThe dispersion of liposomes within a dilute 2% poloxamer solution resulted in a great leakage of pdT16 from liposomes. However, the destabilization effect of poloxamer was reduced when higher concentration (27%) was used. Poloxamer dissolution was found to control the release process of pdT16, whereas the dispersion of liposomes within 27% poloxamer gel was shown to slow down the diffusion of pdT16 out from the gel.
conclusionsThe dispersion of liposomes within a 27% poloxamer gel presented an interesting system to control the release of a model oligonucleotide compare to a simple gel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.